Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02434744 · ClinicalTrials.gov registry record · Phase 2
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 10
- Study locations
NCT02434744: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Response Pharmaceuticals.
NCT02434744 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Response Pharmaceuticals. The registered enrollment target is 121 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02434744, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus.
Primary Outcome
To assess the safety, tolerability, and efficacy (as measured by a 0.5%-1.5% decrease of HbA1c) of different dosages and dosing regimens of a combination of KD026 and metformin compared to placebo and metformin when administered for 3 months to subjects with type 2 diabetes mellitus
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG KD026
Study Locations (10)
California
- Axis Clinical Trials - Los Angeles
- National Research Institute - Los Angeles
- Infosphere Clinical Research, Inc - West Hills
Florida
- Clinical Research of South Florida - Coral Gables
- Med Research of Florida, LLC - Miami
Alabama
- Achieve Clinical Research, LLC - Birmingham
North Carolina
- High Point Clinical Trials Center - High Point
South Carolina
- Coastal Carolina Research Center - Mt. Pleasant
Texas
- Clinical Trial Network - Houston
Virginia
- Clinical Research Associates of Tidewater - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
What the finished NCT02434744 record still lists
NCT02434744 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02434744 lists 10 locations in 7 states (California, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT02434744 about?
NCT02434744 is a clinical study titled "Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus". This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus.
What is the current status of trial NCT02434744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2015-04. Estimated completion is 2016-03.
What conditions does trial NCT02434744 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02434744?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), KD026 (DRUG).
Who is sponsoring clinical trial NCT02434744?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02434744 being conducted?
This trial has 10 study locations across Alabama, California, Florida, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02434744's enrollment target sits among peer trials
121 48th of 130 higher than 83 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia